A novel large fragment deletion in PLS3 causes rare X-linked early-onset osteoporosis and response to zoledronic acid
Fang Lv(Liaoning Normal University), Ke Li(Second Military Medical University), Xiaoping Xing(Chinese Academy of Medical Sciences & Peking Union Medical College), Wei Liu(Sun Yat-sen University), Weibo Xia(Chinese Academy of Medical Sciences & Peking Union Medical College), L. Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Yan Jiang(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhengqing Qiu(Chinese Academy of Medical Sciences & Peking Union Medical College), W. F. Mader(Harbin Institute of Petroleum), Xin‐Jian Xu(Shanghai University), Yuwen Song(Chinese Academy of Medical Sciences & Peking Union Medical College), O. Wang(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 32
Related Papers
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415
Luteolin-loaded solid lipid nanoparticles synthesis, characterization, & improvement of bioavailability, pharmacokinetics in vitro and vivo studies
|Journal of Nanoparticle Research|2014|128
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)
|Annals of Oncology|2013|120
CircCEMIP promotes anoikis-resistance by enhancing protective autophagy in prostate cancer cells
|Journal of Experimental & Clinical Cancer Research|2022|115